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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
￿ The trifunctional antibody catumaxomab is
a highly effective anti-cancer therapeutic
that is administered to patients suffering
from malignant ascites intraperitoneally (i.p.)
in microgram (mg) doses.So far,no clinical
pharmacokinetic data are available.
WHAT THIS STUDY ADDS
￿ Catumaxomab attains effective local
concentrations in the ascites ﬂuid and
shows low systemic exposure with an
acceptable safety proﬁle conﬁrming the
appropriateness of the i.p.application
scheme.
AIMS
Catumaxomab is the ﬁrst EMEA approved trifunctional anti-EpCAM¥anti-CD3
antibody for the treatment of cancer patients with malignant ascites.A phase II
pharmacokinetic study was conducted to determine local and systemic
antibody concentrations and anti-drug antibody (ADA) development.
METHODS
Thirteen cancer patients with symptomatic malignant ascites were treated with
four ascending doses of 10,20,50,and 150 mg catumaxomab intraperitoneally
(i.p.) infused on days 0,3,6 or 7 and 10.The pharmacokinetics of catumaxomab
were studied by implementation of supportive data from a non clinical mouse
tumour model.Additionally,ADA development was monitored.
RESULTS
Ten out of 13 patients were evaluable for pharmacokinetic analysis.
Catumaxomab became increasingly concentrated in ascites during the
course of treatment,attaining effective concentrations in the ng ml
-1 range.
Catumaxomab remained immunologically active even after several days in the
circulation.The observed systemic catumaxomab exposure was low (<1%),with
a maximal median plasma concentration (Cmax)o f4 0 3p gm l -1.The mean
elimination half-life in the plasma was 2.13 days.All patients developed ADA,
but not before the last infusion.High observed inter-individual variability and
low systemic exposure may be explained by the inverse correlation between
tumour burden,effector cell numbers and systemic antibody bioavailability as
demonstrated in a deﬁned mouse tumour model.
CONCLUSIONS
Based on the high and effective local concentrations,low systemic exposure and
acceptable safety proﬁle,we conﬁrmed that the i.p.application scheme of
catumaxomab for the treatment of malignant ascites is appropriate.
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Catumaxomab is a novel trifunctional rat/murine hybrid
antibody that has bi-speciﬁcity for the epithelial cell adhe-
sion molecule, EpCAM and the T-cell antigen, CD3. In
addition, it has a functional constant Fc region that
preferentially binds to Fc-gamma receptors (FcgR) I/IIa and
III [1–4].This trifunctionality leads to effective destruction
of EpCAM-positive tumour cells even at antibody concen-
trations in the pg ml
-1 range [5]. During clinical develop-
ment, the antibody demonstrated convincing efﬁcacy as
anintraperitoneal(i.p.)treatmentforadvancedcarcinomas
associated with malignant ascites (MA) [6]. In MA, the
abnormal accumulation of ﬂuid within the peritoneal
cavity is primarily caused by the spread of epithelial
tumourcells.Themajorityofthesetumourcells(70–100%)
expressEpCAM[7–11].Therefore,therationalefori.p.appli-
cation of catumaxomab was to obtain high local concen-
trations at the site of action. Efﬁcient tumour cell
elimination in the ascites ﬂuid followed by absence of
ascites re-accumulation conﬁrmed the treatment concept
[6, 12]. In a dose escalating study, the maximal tolerated
dose (MTD) was deﬁned at ﬁve i.p. infusions of 10, 20, 50,
200, and 200 mg, administered within 9–13 days [12]. The
main side-effects, including fever, nausea, and vomiting,
were fully reversible and consistent with the mode of
action of catumaxomab. The dose escalation scheme
employed a low starting dose based on the facts that i)
i.p. administration of catumaxomab was associated with
symptoms attributed to cytokine release and ii) the
patientsdidnottoleratehighstartingdoses.Insubsequent
infusions,high doses of catumaxomab were generally well
tolerated. Most of the patients developed anti-drug
antibodies (ADA) against the mouse and rat sequences of
catumaxomab, but not before the last infusion [6, 12, 13].
Finally, these clinical parameters were implemented in a
pivotal phase II/III study that showed that catumaxomab
signiﬁcantly prolonged puncture-free survival in patients
with MA [14] leading to market approval of catumaxomab
inEurope.Here,wereporttheresultsfromthecorrespond-
ing pharmacokinetic trial.The main study objectives were
to determine local and systemic concentrations of catu-
maxomab and establish its safety proﬁle. In addition, we
present supporting data on the bioavailability of catumax-
omab gained from a mouse tumour model.
Methods
Patients
Thirteen patients with cancer, symptomatic MA,
and immunocytochemically conﬁrmed EpCAM-positive
tumour cells (400 in 10
6 analysed ascites cells) were
treated. The most frequent type of primary tumour was
ovarian (69%), followed by pancreatic (23%), and gastric
(8%)carcinoma.Twopatientswhoreceivedonlythreeinfu-
sions, and one patient who was ADA positive before
treatment,wereexcludedfromthepharmacokineticevalu-
ation. The study was conducted in accordance with the
DeclarationofHelsinki(AddendumfromWashington,2002
to the EdinburghVersion of 2000),and it was approved by
the local authorities and independent ethics committees
relevant to the centres involved.Written informed consent
was obtained from each patient.
Pharmacokinetic study design
An open-label,phase II pharmacokinetic study was carried
out at two centres in Romania and three centres in
Germany. Patients with cancer and MA were treated with
four ascending doses of the therapeutic antibody catu-
maxomab (10,20,50,and 150 mg) on days 0,3,6 or 7,and
10. The antibody was diluted in 0.9% NaCl solution and
administered i.p.in a 6 h constant rate infusion via an ind-
welling catheter. To allow optimal distribution, 500 ml of
0.9% NaCl solution was given to patients before the appli-
cation of the therapeutic antibody. To reduce adverse
eventsrelatedtocytokinerelease,1000 mgofparacetamol
was administered 30 min before each infusion as a
premedication. Efﬁcacy measurements and immunocy-
tochemicalanalysisofascitestumourcellswereperformed
as described previously [12].The primary study objective
was the determination of local and systemic catumax-
omab concentrations. Therefore, ascites samples were
taken at screening and prior to each catumaxomab infu-
sion. Blood samples (7.5 ml) were collected pre-infusion,
24 haftertheﬁrstinfusion,andattheindicatedtimepoints
after the third and fourth infusions. Additional samples
werecollectedfromtwopatientsafterthesecondinfusion,
but no catumaxomab antibody was detected.The heparin
plasma preparations were performed at the study site,and
aliquoted samples were frozen within 1 h of collection.All
samples were stored frozen (-80°C) until measurement.
Determination of catumaxomab concentrations
Plasma catumaxomab concentrations were measured by a
validated two-site ELISA. Brieﬂy, catumaxomab was cap-
tured by an anti-rat IgG l light chain-speciﬁc antibody
(LA1B12, TRION Research, Munich, Germany). Bound
catumaxomab was then detected via an anti-mouse
IgG2a-speciﬁc biotin-labeled detection antibody
(BD Pharmingen, San Diego, CA). Then, streptavidin-
b-galactosidase and its corresponding substrate,
chlorphenolred-b-D-galactopyranosid (Roche Diagnostics,
Mannheim, Germany), were added, and the colorimetric
reaction was measured at 570 nm.Catumaxomab concen-
trations were calculated by interpolation on a standard
curve.The lower limit of quantiﬁcation (LLOQ) of the assay
wasdeterminedtobe125 pg ml
-1;theupperlimitofquan-
tiﬁcation was 4000 pg ml
-1. All samples were diluted 1:2
and subjected to a delipidation step before measuring in
duplicate. Spike recoveries were performed with pre-
therapy samples of all patients and the reciprocal values
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was 107% (17.21 SD). Post-study quality control (QC)
sample analysis demonstrated an overall inter-assay preci-
sion of 5.5% CV and an overall assay accuracy of 99.2%.
Assay-interfering ADA were effectively blocked with the
use of an in-house developed blocking agent that con-
sistedofisotype-matchedratandmousemonoclonalanti-
bodies.All ADA-positive samples were re-measured in the
presence of the blocking agent.In about 9% of the plasma
sampleswithveryhighADAconcentrations,assayinterfer-
ence could not be completely eliminated.The results from
these samples were considered invalid and were not used
for PK calculations.
For quantiﬁcation of catumaxomab in ascites ﬂuid,the
ELISA was adapted to the ascites matrix. The analytical
range of the assay was 250–8000 pg ml
-1.
Evaluation of bioactivity in a potency assay
The immunological activity,also referred to as cytotoxcity
in ascites and plasma samples, was indirectly evaluated
with an XTT (tetrazolium hydroxide) proliferation assay.
Brieﬂy,1 ¥ 10
5 peripheral blood mononuclear cells (PBMC)
were mixed with 1 ¥ 10
4 EpCAM-positive HCT-8 tumour
cells (ATCC CCL-244) in 96-well ﬂat bottomed plates.
Sampleswereaddedata1:10(ascites)or1:5(plasma)dilu-
tion,and plates were cultivated at 37 °C and 5% CO2.After
3 days, the culture supernatants were collected for cytok-
ine measurement byTh1/Th2 cytometric bead array (CBA)
assay, according to the manufacturer’s instructions (BD
Pharmingen, San Diego, CA).The cytokine concentrations
of IL-2, IL-4, IL-6, Il-10, IFN-g and TNF-a were determined.
The remaining adherent tumour cells were stained with
the XTT cell proliferation kit II (Roche Diagnostics GmbH,
Mannheim, Germany) after soluble PBMC had been
removed by washing twice with PBS. The tumour cell
killing efﬁciency was assessed in two independent experi-
ments with triplicate determinations of each sample, as
described previously [5]. Final catumaxomab assay con-
centrations ranged between 300 and 4000 pg ml
-1, and
resulted in signiﬁcant tumour cell killing (32–90%).Spiked
controls were made by adding fresh catumaxomab to
pre-therapy ascites or plasma samples from the corres-
ponding patients. Additionally, pre-therapy non-spiked
samples served as matrix controls. The % bioactivity
was calculated according to the formula: (%
killing sample/% killing spiking control) ¥ 100%.
Analysis of anti-drug antibodies
Anti-drug antibodies in plasma samples were analysed
with a validated bridging ELISA at Experimentelle und
Diagnostische Immunologie (EDI) GmbH (Reutlingen,
Germany). Brieﬂy, catumaxomab was immobilized to the
surface of a multititre plate as a capture antibody.Samples
were added, and antibodies that bound catumaxomab
weredetectedbyaddingbiotinylatedcatumaxomab.Next,
a streptavidin-b-galactosidase conjugate was added, and
the ADA were quantiﬁed photometrically at 570 nm. The
monoclonal mouse antibody LA1B12 (TRION Research,
Germany) was used to calibrate the ADA concentrations.
This antibody recognizes the rat l light chain of catumax-
omab, and it was shown to generate dose–response
curves similar to those generated by polyclonal anti-
catumaxomab sera.The LLOQ of the assay was 13 ng ml
-1.
Pharmacokinetic evaluation
All kinetic parameters were determined independently of
a model with a non-compartmental method in the Win-
Nonlin,version 4.1 (Pharsight corporation,Mountain View,
CA) software program. Pharmacokinetic characteristics
were determined directly from the measured concentra-
tions. Actual sampling times were used for pharmacoki-
netic evaluations. The pharmacokinetic parameters used
for systemic catumaxomab were AUC(0,tlast),Cmax,tmax,Cmax3,
and Cmax4 (the latter two parameters are the maximal
plasma concentrations after the third and fourth infusions,
respectively). The AUC was calculated by a log
linear·trapezoidal method.The apparent terminal elimina-
tion rate constant lz was determined by log-linear regres-
sion analysis using three time points. The terminal
elimination half-life t1/2 was calculated according to the
equation t1/2 = ln2/lz.
Non-clinical mouse study
A non-clinical pharmacokinetic study with catumaxomab
antibody was performed in female C.B-17 SCID mice at
Aurigon Life Science GmbH (Tutzing, Germany) in accor-
dance with the local government requirements.Catumax-
omab was administered either i.v. (group I) or i.p. (groups
II-IV) at 100 mgk g
-1 body weight. Additionally, groups III
and IV received SKOV-3 tumour (ATCC HTB-77) and PBMC
effectorcells,bothat2¥10
6(groupIII)or1¥10
7(groupIV)
per mouse.Cells were applied i.p.shortly before the catu-
maxomab injection; the total injection volumes were
500 ml i.p. and 100 ml i.v. For pharmacokinetic evaluation,
blood samples were taken from the retro-orbital plexus
underslightetheranaesthesiaat10 min,2,4,8,24,and72 h
after catumaxomab administration. Plasma samples were
prepared, frozen (-80 °C), and stored until catumaxomab
quantiﬁcation was performed atTRION Research by apply-
ingtheabove-mentionedELISA,adaptedtomouseplasma
matrix. The number of EpCAM surface molecules on
SKOV-3 ovarian cancer cells was quantiﬁed on the day of
injection by means of immunoﬂuorescence staining using
the Qiﬁkit (DakoCytomation, Glostrup, Denmark) and the
EpCAM-speciﬁc antibody, HO-3 [5]. Pharmacokinetic
parameters were based on the mean plasma concentra-
tions of catumaxomab (n = 5 per timepoint) and were cal-
culated with the WinNonlin® software (version 5.0.1;
Pharsight Corporation, Mountain View, CA) in a non-
compartmental manner. The observed i.p. bioavailability
was calculated relative to the i.v. route with the equation:
Fobs = AUC(0,last)i.p. route/AUC(0,last)i.v. route
Pharmacokinetics of intraperitoneally administered catumaxomab
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Ascites catumaxomab concentrations increased
during the course of treatment
Ten out of 13 patients with MA who received all four catu-
maxomab infusions of 10,20,50,and 150 mg delivered into
the peritoneal cavity were evaluable for pharmacokinetic
analysis. Before each infusion, ascites ﬂuid was drained.
Thus,sampleswereavailablepre-treatmentandeach3to4
days after the 10, 20, and 50 mg dosages. Analysis of the
samples revealed quantiﬁable catumaxomab concentra-
tions in all patients except patient 108/102 (Figure 1). All
pre-treatment samples were below LLOQ (125 pg ml
-1).
After the ﬁrst infusion of 10 mg,catumaxomab was readily
detectable in most patients.There was an overall trend of
increasing concentrations with the increasing doses.
Median antibody concentrations in the ascites rose from
552toover1721andthento6121 pg ml
-1,inproportionto
thedosingschemeof10,20,and50 mg.Theinter-individual
variability was high; the ascites catumaxomab concentra-
tions ranged from 0 to 39 912 pg ml
-1 at day 10 (SD =
12 414).
Systemic catumaxomab exposure was low
Because unbound catumaxomab was observed in the
ascites ﬂuid of most patients,we investigated whether the
antibodymighthaveescapedintothesystemiccirculation.
Indeed,quantiﬁableplasmaconcentrationswereobserved
in nine patients after the third and fourth infusions
(Table 1). However, in general, plasma catumaxomab con-
centrations were much lower than those measured in the
ascites ﬂuid. The median maximum concentration (Cmax)
was 403 pg ml
-1. Again, inter-individual variability was
high; the systemic catumaxomab Cmax ranged from 0 to
2290 pg ml
-1, and the individual area under the curve
over the treatment period (AUC(0,tlast)) varied from 0 to
10 020 pg ml
-1 day.The presence of high concentrations in
the ascites did not always correlate with increased plasma
concentrations. For example, patient 805/101 showed the
highest measurable catumaxomab concentrations in
ascitesﬂuid,buthadnodetectableantibodyintheplasma.
Individual concentration proﬁles over time exhibited
increasing concentrations in plasma after the third anti-
body infusion; however, the concentrations declined
before the fourth antibody application (Figure 2). In most
patients, plasma catumaxomab concentrations peaked
after the last (fourth) infusion, reﬂecting the increase in
dose from 50 to 150 mg.The median plasma Cmax after the
fourth infusion was about ﬁve times higher than the
median after the third infusion (398 vs. 82 pg ml
-1,respec-
tively).No catumaxomab was detected in the plasma after
the ﬁrst (10 mg) or second (20 mg) infusion.The maximum
systemic exposure was reached at approximately 19 h
(tmax) from the end of the last infusion.The mean terminal
eliminationhalf-life(t1/2)was2.13days,basedondatafrom
seven patients.
Tumour burden and effector cells inﬂuenced
the bioavailability of catumaxomab
Catumaxomab has binding sites for EpCAM on tumour
cells,for CD3 onT-cells,and for FcgR on accessory immune
cells;thus,thistrifunctionalantibodyisexpectedtoexhibit
complex pharmacokinetics. As anticipated, we observed
largeinter-individualdifferencesinlocalandsystemicanti-
body concentrations. Tumour load and immune effector
cell numbers at the site of application were expected to
inﬂuence the pharmacokinetics. Indeed, there were large
differences among patients in the amounts of EpCAM-
positive tumour cells in the ascites ﬂuid (range 0.8–39 ¥
10
6) at the time of screening.However,it is difﬁcult to esti-
mate the total tumour burden in patients with progressive
cancer. Therefore, we investigated this question in a
deﬁned non-clinical mouse tumour model. Severe com-
bined immunodeﬁcient (SCID) mice were pretreated with
an i.p.dose of human peripheral blood mononuclear cells
(PBMC) and EpCAM-positive human ovarian tumour cells
(SKOV-3). Then mice were treated with catumaxomab,
given intravenously (i.v.) or i.p. at a dose of 100 mgk g
-1
body weight. In the absence of binding partners, the
observed bioavailability (Fobs) of catumaxomab was 82%.
The bioavailability signiﬁcantly declined to 68% and 27%
in the presence of low or high levels, respectively, of
tumour and effector cells (Table 2).Similar decreases were
observed in Cmax. By quantifying the number of EpCAM
molecules per SKOV-3 tumour cell (3 ¥ 10
5),we calculated
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Figure 1
Individual (symbols) and median (–) catumaxomab ascites concentra-
tions observed during the course of treatment.Intraperitoneal infusions
a r ei n d i c a t e db ya r r o w s .T h et h i r di n f u s i o n( 5 0 mg) was administered
either on day 6 or 7.Ascites samples were taken immediately before the
second,third,andfourthinfusions.108/102( );118/101( );805/101( );
805/102 ( );805/103 ( );805/107 ( );805/108 ( );805/112 ( );805/113
( );808/101 ( );Median ( )
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theoretical maximal reduction in bioavailable catumax-
omab (Fexp = 75 and 51%). However, the observed reduc-
tion in bioavailability was about twice as high as expected.
This can be readily explained by the additional binding of
catumaxomab to the co-injected PBMC effector cells. In
summary, both the tumour cell load and the effector cell
count strongly inﬂuenced the systemic availability of catu-
maxomab.In addition,catumaxomab demonstrated quan-
titative binding. Consequently, these data may at least
partly explain the heterogenic pharmacokinetics from
patients who received i.p.catumaxomab therapy.
High in vivo stability of catumaxomab
The ELISA-based quantiﬁcation of catumaxomab does not
allow conclusions about the antibody’s maintenance of in
vivo immunological activity;thus,we addressed this ques-
tion by analysing suitable samples in a potency assay.
According to its mode of action, the clinical efﬁcacy of
catumaxomab is exerted by the destruction of tumour
cells in the ascites ﬂuid via activation and redirection of
different types of immune effector cells [3]. Therefore,
ascites and plasma samples were tested for their killing
activity against EpCAM-positive tumour cells.The biologi-
cal activity in the samples was compared with control
samples that were freshly spiked with matched concentra-
tions of catumaxomab. As depicted in Figure 3a, analysed
ascitessamplesrevealedcompleteornearlycompletebio-
logical activity relative to the spiked controls, ranging
between 111 and 84%.In contrast,catumaxomab negative
pre-therapy samples displayed only background levels or
low nonspeciﬁc matrix effects. Remarkably, the plasma
samples exhibited 50–60% biological activity at the end of
the last infusion and 2 days later. Moreover, the cytokine
release induced by ascites and plasma samples was
comparable with that observed with spiked controls, as
demonstrated by measurement of TNF-a concentrations
(Figure 3b).Similar results were obtained for IL-2,IL-6,Il-10,
and IFN-g (data not shown).Taking into account the long
interval between drug application and sampling, these
dataconﬁrmedthehighinvivostabilityofi.p.administered
Table 1
Pharmacokinetic parameters of systemic catumaxomab exposure after i.p.administrations of 10,20,50,and 150 mg
Patient ID
AUC(0,tlast)
(pg ml-1 day)
Cmax
(pg ml-1)
% estimated
systemic exposure*
tmax
(h)
Cmax3
(pg ml-1)†
Cmax4
(pg ml-1)‡
lz
(1 day-1)
t1/2
(days)
108/102 177 171 0.28 2.64 0 171 0.9441 0.73
118/101 942 198 0.33 16.32 0 198 0.3340 2.08
805/101 00 0 – 0 0 – –
805/102 10 020 2290 3.82 17.04 1108 2290 0.4288 1.62
805/103 1 819 431 0.72 26.40 0 431 0.2170 3.19
805/107 2 270 375 0.62 17.76 163 375 0.3003 2.31
805/108 3 386 968 1.61 27.60 248 968 0.1995 3.47
805/112 63 101 0.17 17.28 0 101 – –
805/113 3 890 531 0.89 3.36 531 420 – –
808/101 2 616 620 1.03 41.52 231 620 0.4634 1.5
Statistics
n 10 10 10 9 10 10 7 7
Mean 2 518 569 0.95 19 228 557 0.4124 2.13
SD 2 978 668 1.11 12 354 670 0.2542 0.96
Median 2 045 403 0.67 17 82 398 0.3340 2.08
Minimum 0 0 0 2.64 0 0 0.1995 0.73
Maximum 10 020 2290 3.82 41.52 1108 2290 0.9441 3.47
*Based on the last and highest infusion dose (150 mg) and assuming a total plasma volume of 2500 ml, the systemic exposure was calculated as follows: Cmax ¥ 2500/(150 ¥ 106)
¥ 100%. †maximal measured concentration after the third infusion (50 mg). ‡maximal measured concentration after the fourth infusion (150 mg).
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Figure 2
Individual catumaxomab plasma concentration vs. time proﬁles in 10
patients. Intraperitoneal infusions of catumaxomab are indicated by
arrows.The third (50 mg) infusion was administered either on day 6 or 7.
Catumaxomab was detectable in the plasma only after the third and
fourth infusions. 108/102 ( ); 118/101 ( ); 805/101 ( ); 805/102
( ); 805/103 ( ); 805/107 ( ); 805/108 ( ); 805/112 ( );
805/113 ( );808/101 ( )
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several days in the circulation. Moreover, despite low sys-
temic plasma concentrations in the pg ml
-1 range, these
concentrations were sufﬁciently potent to induce tumour
cell killing.
Evaluation of anti-drug antibody (ADA)
development and safety
The rat/murine chimeric antibody catumaxomab is immu-
nogenicinman[6,12,13].Thisﬁndingwasconﬁrmedinthis
study,because all patients developed ADA (Figure 4).ADA
development was highly dynamic,with measured concen-
trationsthatdifferedbyseveralordersofmagnitude,prob-
ably reﬂecting the diverse immune status of patients with
late stage cancer. The highest observed value was
60 000 ng ml
-1. Of note, none of the patients developed
signiﬁcantADAresponses(>100 ng ml
-1)beforethetimeof
the last infusion. In most patients, ADA onset occurred
betweendays11and16.Theseﬁndingssupporttheappro-
priateness of the clinical application schedule that termi-
nates catumaxomab treatment before ADA development.
Thus,ADA-basedsafetyorefﬁcacyissuesarecircumvented.
Moreover,catumaxomab infusions were well tolerated
with acceptable toxicities. Commonly observed adverse
events, including pyrexia/chills, nausea/vomiting, dysp-
noea, and hypotension/hypertension occurred at mild to
moderate levels and were reversible.Cytokine release and
transient increases in liver enzymes were similar to the
safety ﬁndings of previous studies [6, 12] and consistent
with the mode of action of catumaxomab. Importantly,
there was no apparent relationship between systemic
exposure and the adverse clinical ﬁndings.
Discussion
MA is an end stage manifestation, mainly observed in
patients with progressive ovarian and gastrointestinal
cancer, and it is associated with poor prognosis [7].
Affected patients experience a dramatic impairment in
quality of life due to abdominal pain, nausea, anorexia,
dyspnoea and other symptoms [15].The spread of tumour
cellsinﬁltratingtheperitoneumrepresentsthemaincause
of abnormal accumulation of body ﬂuid in the peritoneal
cavity. Consequently, a direct attack on these inﬁltrating
tumour cells should lead to effective relief of MA symp-
toms. This approach has been successfully pursued with
the trifunctional antibody catumaxomab (anti-EpCAM ¥
anti-CD3) that,when given i.p.,speciﬁcally targets EpCAM-
positive tumour cells [6,13].As EpCAM is also expressed in
normal epithelium [16], the rationale for i.p. application
wastoachievehighlocalconcentrationsandthusdiminish
potential negative side-effects.
Indeed, effective catumaxomab concentrations were
determined in nine of 10 evaluable patients in the ascites
ﬂuid. A median concentration of 552 pg ml
-1 was mea-
sured 3 days after the starting dose of 10 mg. This repre-
sents an effective dose level, as catumaxomab has
demonstrated signiﬁcant capacity for killing tumour cells
even at concentrations of 1000–100 pg ml
-1 [5]. Efﬁcient
tumour cell reduction in the ascites was consistently
observed after the ﬁrst 10 mg dose;the median number of
EpCAM-positive tumour cells was reduced from 9362
(screeningvalue)to49(beforethesecondinfusion)per10
6
total ascites cells in this study. In the course of treatment,
catumaxomab concentrations in the ascites further
increased in proportion to the escalating infusion doses.
Concomitantly,the median number of tumour cells in the
ascites dropped to zero. Furthermore, catumaxomab
exhibited a remarkable in vivo stability.Even after 3 days in
ascites,the antibody remained biologically active without
signiﬁcant loss in its ability to induce tumour cell killing
and cytokine release.These data support the clinical efﬁ-
cacy of catumaxomab previously observed in the treat-
ment of MA [6,12,14]) and peritoneal carcinomatosis [17].
In accordance with the antibody stability in ascites, we
Table 2
Inﬂuence of tumour (SKOV-3) and immune effector cells (PBMC) on the pharmacokinetics of catumaxomab in SCID mice
Group (n)
Application
route
SKOV-3 cell
number
EpCAM binding
sites*
PBMC
number
Cmax
(ng ml-1)
tmax
(h)
Clast
(ng ml-1)
tlast
(h)
AUC(0,last)
(ng ml-1 h)
Fobs
(%)
Fexp
(%)†
I (5) i.v. – – 1879 0.17 488 72 45 669 100 –
SE 132 2 253
II (5) i.p. – – 733 4 565 72 37 465 82 –
SE 56 3 489
III (5) i.p. 2 ¥ 106 6 ¥ 1011 2 ¥ 106 665 8 278 72 30 879 68 75
SE 60 2 437
IV (5) i.p. 1 ¥ 107 3 ¥ 1012 1 ¥ 107 287 2 81 72 12 483 27 51
SE 123 3 461
Catumaxomab was applied at 100 mgk g -1 body weight, which corresponds to 8 ¥ 1012 antibody molecules per 20 g mouse. Groups III and IV additionally received EpCAM-positive
tumour and PBMC effector cells pre-injected i.p. The inﬂuence on the bioavailability (F) of i.p. administered catumaxomab was evaluated. SE, Standard error; SKOV-3, human ovarian
cancer cell line; EpCAM, epithelial cell adhesion molecule; PBMC, peripheral blood mononuclear cells; SCID, severe combined immunodeﬁciency. *Total EpCAM binding sites: SKOV-3
cell number ¥ 3 ¥ 105 (quantiﬁed EpCAM molecules per cell); †expected bioavailability assuming quantitative binding to EpCAM: 82% – (EpCAM binding sites/8 ¥ 1012 (applied
catumaxomab molecules) ¥ 100%.
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relativelylong,comparedwithmostothermurineIgGanti-
bodies [18–20], and may be ascribed to the rat/murine
hybrid nature of catumaxomab.
Compared with the amount of antibody detected in
the ascites, much lower concentrations were detected in
the plasma, and only after the third and particularly the
fourth infusion. For the last and highest infusion dose
(150 mg), a mean of only 0.95% of the i.p. administered
catumaxomab was detected in the periphery as unbound
antibody (Table 1). In contrast to the obvious assumption
that most of the antibody in the peripheral blood may be
bound to T cells via its CD3 binding arm spiking experi-
ments revealed that 80–90% of catumaxomab were not
cell bound (data not shown).This can be readily explained
by the intermediate afﬁnity of catumaxomab to CD3 (KD =
4.4 nM) which does not allow quantitativeT-cell binding at
very low antibody concentrations.Interestingly, there was
no correlation between the systemic plasma concentra-
tions and adverse clinical ﬁndings. This corroborates the
notion that side-effects were mainly derived from locally
acting catumaxomab and the observed low systemic con-
centrations of catumaxomab did not raise any safety con-
cerns.Ontheotherhand,despitethelowlevelsofantibody
concentrationsintheplasma,theselevelscouldeffectively
causethedestructionoftumourcellsinvitro.Itistempting
to speculate that patients might beneﬁt from additional
systemic effects under these conditions.This suggests that
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Figure 3
Bioactivityofcatumaxomabinascitesandplasmasamples.Bioactivitywasdeterminedinapotencyassaythatevaluatedascitesandplasmasamplesforthe
abilities to A) kill EpCAM-positive HCT-8 tumour cells and B) secreteTNF-a cytokine,relative to controls with freshly spiked catumaxomab.Ascites samples
were obtained before the third or fourth infusion from ﬁve patients,and two plasma samples were obtained from one patient
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Br J Clin Pharmacol / 69:6 / 623the third and fourth infusion doses may play an important
role in the clinical effects.As expected from previous ﬁnd-
ings, all patients developed ADA, but not before termina-
tion of treatment; this obviated problems with safety or
efﬁcacy.ADA appearance was highly dynamic and potent
which reﬂects the intrinsic immunogenicity of the T-cell
engaging catumaxomab, that was probably enhanced by
its repeated i.p. application [21]. Interestingly, when a
single i.v. infusion dose of 2–7.5 mg of catumaxomab was
given to patients with non-small cell lung cancer,it did not
provoke ADA development [22].
As expected, considering the different degrees of
tumour burden, immune cell status and permeability of
thediseasedperitoneum,therewashighinter-patientvari-
ability in the local and systemic catumaxomab concentra-
tions. Although individual ascites volumes had no major
impact on the variability (data not shown),the number of
available binding sites was important. This was demon-
strated in the pharmacokinetic study performed in mice.
High local numbers of EpCAM-positive tumour and PBMC
effector cells signiﬁcantly reduced the bioavailability of
catumaxomab in the systemic circulation. An inverse cor-
relation between systemic antibody concentrations and
tumour bulk has also been reported and discussed in
studies of other tumour-speciﬁc monoclonal antibodies,
including rituximab and alemtuzumab [23–25]. The tri-
functional antibody catumaxomab additionally binds to
T-cells and FcgR positive immune cells; thus, the presence
of these binding partners is of equal importance for its
distribution. Of note, an increased number of CD45-
positive leukocytes appeared in the peritoneal cavity after
catumaxomab application [12]. These results suggested
that high local tumour burden and immune effector cell
accumulation might be the major causes for inter-
individual variability and the observed low systemic
exposure.
In summary, catumaxomab administered i.p. for the
treatment of MA demonstrated high in vivo stability,effec-
tive local concentrations in ascites ﬂuid, minor systemic
exposure,and an acceptable safety proﬁle.
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